Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB5121 open-label phase 1b/2 study in relapsed or refractory primary or secondary CNS lymphoma
MOH_2022-06-09_010630Phase 2Not yet recruiting
- Sponsor
- GB005, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GB5121 in primary central nervous system lymphoma (PCNSL), vitreoretinal lymphoma (PVRL) and secondary central nervous system lymphoma (SCNSL) (3 arms), sponsored by GB005, Inc. Primary endpoints: Safety and tolerability of escalating doses of GB5121, Maximum tolerated dose and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
GB5121
03
Conditions
primary central nervous system lymphoma (PCNSL)vitreoretinal lymphoma (PVRL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on MOH_2022-06-09_010630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-09_010630.